Allopurinol

Catalog No.S1630

For research use only.

Allopurinol is a purine analog inhibitor of the enzyme xanthine oxidase, used to treat gout or kidney stones, and to decrease levels of uric acid.

Allopurinol  Chemical Structure

CAS No. 315-30-0

Selleck's Allopurinol has been cited by 13 publications

Purity & Quality Control

Choose Selective ROS Inhibitors

Biological Activity

Description Allopurinol is a purine analog inhibitor of the enzyme xanthine oxidase, used to treat gout or kidney stones, and to decrease levels of uric acid.
Targets
xanthine oxidase [1]
In vitro

Allopurinol reverses the increased xanthine oxidase activity in ischemia-reperfusion injury of neonatal rat hearts. Allopurinol (10 mM) treatment suppresses xanthine oxidase activity induced by hypoxia-reoxygenation injury and the production of reactive oxygen species. Allopurinol also decreases the concentration of intracellular Ca2+ increased by enhanced xanthine oxidase activity. [1]

In vivo Allopurinol shows abnormal pyrimidine metabolism together with renal toxicity which could be ameliorated by uridine, indicating that Allopurinol essentially causes pyrimidine metabolism abnormality leading to renal impairment in normal mice. Allopurinol increases urinary OD excretion to an extent similar to that in normal mice administered the same dose of Allopurinol in DNFB-sensitized mice. [2] Allopurinol promotes a clinical improvement which is accompanied by a reduction in the parasitic load in the blood, skin and lymph nodes but, even after long period of allopurinol administration alone, Leishmania may persist in dog tissues in Leishmania-infected dogs. [3] Allopurinol prevents early alcohol-induced liver injury in rats, most likely by preventing oxidant-dependent activation of NF-kappaB. [4] Allopurinol protects dose-dependently against acetaminophen-induced cell injury, the loss of ATP and the increase of the GSSG content in the total liver and in the mitochondrial compartment without inhibiting reactive metabolite formation in mice. Allopurinol almost completely inhibits hepatic xanthine oxidase and dehydrogenase activity, but only high doses prevents the increase of the mitochondrial GSSG content. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 27 mg/mL
(198.36 mM)
Water 4 mg/mL
(29.38 mM)
Ethanol 3 mg/mL
(22.04 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 136.11
Formula

C5H4N4O

CAS No. 315-30-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=NNC2=C1C(=O)NC=N2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04853615 Not yet recruiting Drug: Empagliflozin 25 MG SGLT2i Kideny Protection Against Contrast in Diabetic Kidney Fayoum University|Cairo University July 1 2021 --
NCT04026776 Recruiting Drug: Allopurinol|Other: Dietary Intervention Salt; Excess|Blood Pressure Disorders Wake Forest University Health Sciences|National Heart Lung and Blood Institute (NHLBI) September 2 2020 Early Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Allopurinol | Allopurinol supplier | purchase Allopurinol | Allopurinol cost | Allopurinol manufacturer | order Allopurinol | Allopurinol distributor